<DOC>
	<DOCNO>NCT00719225</DOCNO>
	<brief_summary>To make belatacept available recipient renal allograft currently intolerant contraindication CNIs and/or m-TOR inhibitor either : - unable construct adequate immunosuppression regimen due non-renal toxicity / contraindication ( withdraw causative agent would lead renal graft loss ) OR - imminent risk lose allograft kidney due nephrotoxicity option renal replacement therapy</brief_summary>
	<brief_title>A Belatacept Compassionate Use Study Patients With Kidney Transplant</brief_title>
	<detailed_description />
	<mesh_term>Abatacept</mesh_term>
	<criteria>Please call 8003989157 information study Men woman age 18 year older inclusive Recipient renal allograft least ≥ 2 month EBV positive Unable tolerate suitable immunosuppression regimen prevent acute allograft rejection , due : Extrarenal toxicity relate CNIs and/or mTOR inhibitor refractory medical management ( eg , uncontrolled seizure ) Contraindication CNIs and/or mTOR inhibitor OR At imminent risk lose allograft kidney due nephrotoxicity Renal failure : ≥ Stage 4 KDOQI Scale ( GFR 15 29 cc/min ) And renal replacement therapy Subjects must receive maintenance immunosuppressant MMF , MPA , AZA Any significant infection , extrarenal solid organ ( heart , liver , pancreas ) cell ( islet , bone marrow , stem cell ) transplant , unresolved episode AR within last 6 week EBV negative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>